Press Releases by "Kissei Pharmaceutical Co., Ltd."

• Announcement of an Agreement for the Co-Promotion of an immunosuppressant Imuran® Tablets 50 mg
  [ Pharmaceuticals | 2016-12-15]
• Japanese NDA for an ulcerative colitis treatment agent (Development code: AJG511) was filed.
  [ Pharmaceuticals | 2016-10-28]
• Kissei and JCR to Initiate a Phase III Clinical Trial of a Long-Acting Erythropoiesis-Stimulating Agent (Development Code: JR-131)
  [ Pharmaceuticals | 2016-08-09]
• Announcement of the Launch of Glufast ® OD Tab. (Orally Disintegrating Tablets)
  [ Pharmaceuticals | 2016-06-16]
• Announcement of Additional Clinical Trial of “KPS-0373 (Development Code)” for the Treatment of Spinocerebellar Ataxia
  [ Pharmaceuticals | 2016-05-27]
• Kissei and Kyorin signed an Agreement for Co-Development and Co-Marketing of KRP-114V
  [ Pharmaceuticals | 2016-03-30]
• Announcement of the Launch of Urief® OD Tab. (Orally Disintegrating Tablets) for the Treatment of Dysuria Associated with Benign Prostatic Hyperplasia in Japan
  [ Pharmaceuticals | 2016-01-15]
• Announcement of the Launch of “P-TOL® Chewable Tab.”for the Treatment of Hyperphosphatemia in Japan
  [ Pharmaceuticals | 2015-11-26]
• Kissei Announces Licensing Agreement with ObsEva SA for KLH-2109, a Novel Investigational Drug for the Treatment of Endometriosis
  [ Pharmaceuticals | 2015-11-20]
• New Drug Application Approval for “P-TOL® Chewable Tablets” for the Treatment of Hyperphosphatemia in Japan
  [ Pharmaceuticals | 2015-09-28]
• Kissei and Ajinomoto Pharmaceuticals announce partnership for joint development and marketing of AJM300 and AJG511 for treatment of ulcerative colitis in Japan
  [ Pharmaceuticals | 2015-03-31]
• Kissei Pharmaceutical Co., Ltd. Receives Approval in Japan for Additional Indication and Dosage and Administration of DOPRAM® Injectable 400mg for Primary Apnea in Premature and Low-Birth-Weight Infants (Apneic Attack of Prematurity)
  [ Pharmaceuticals | 2015-03-20]
• Announcement of the Launch of “SALAGEN® Granules 0.5%” for the Treatment of Dry Mouth Symptoms
  [ Pharmaceuticals | 2014-12-12]
• New Drug Application Submitted for “PA21 (development code)” for Treatment of Hyperphosphatemia
  [ Pharmaceuticals | 2014-11-19]
• Kissei Pharmaceutical Co., Ltd. submits a public knowledge-based application for a respiratory stimulant DOPRAM® injectable 400mg for the additional indication of an apneic attack of prematurity
  [ Pharmaceuticals | 2014-05-20]
• Announcement of the death of our company’s Honorary Chairman, Kunio Kanzawa (former Chairman)
  [ Pharmaceuticals | 2014-05-14]
• Announcement on change of President
  [ Pharmaceuticals | 2014-04-25]
• Announcement of the launch of “SAVENE® Injectable 500mg” for the Treatment of Anthracycline Extravasation in Japan
  [ Pharmaceuticals | 2014-04-17]
• Kissei Announces Business Collaboration Agreement with Alteogen
  [ Pharmaceuticals | 2014-02-13]
• New Drug Application Approval for "SAVENE® Injectable 500mg" for the Treatment of Anthracycline Extravasation in Japan
  [ Pharmaceuticals | 2014-01-17]

Most Popular: "Kissei Pharmaceutical Co., Ltd."